Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: the multicentre, prospective CAP-Asia study

التفاصيل البيبلوغرافية
العنوان: Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: the multicentre, prospective CAP-Asia study
المؤلفون: Yong‐Wen Leow, Wah‐Kheong Chan, George Boon‐Bee Goh, Vincent Wai‐Sun Wong, Jian Gao Fan, Young Seok Kim, Seung Up Kim, Atsushi Nakajima, Wai‐Kay Seto, I‐Cheng Lee, Yi‐Hsiang Huang, Yoon Jun Kim, Jang Jae Young, Wan Cheng Chow
المصدر: Journal of viral hepatitis.
سنة النشر: 2022
مصطلحات موضوعية: Infectious Diseases, Hepatology, Virology
الوصف: We aimed to compare the severity of liver disease, metabolic profile and cardiovascular disease (CVD) risk of chronic hepatitis B (CHB) patients with and without hepatic steatosis and patients with non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD and CHB were prospectively enrolled from ten Asian centres. Fibroscan was performed for all patients and hepatic steatosis was defined based on controlled attenuation parameter248 dB/m. CVD risk was assessed using the Framingham risk score. The data for 1080 patients were analyzed (67% NAFLD, 33% CHB). A high proportion (59%) of CHB patients had hepatic steatosis. There was a significant stepwise increase in alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transpeptidase, controlled attenuation parameter and liver stiffness measurement, from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients (p0.001 for all comparisons). There was a significant stepwise increase in the proportion of patients with metabolic syndrome and in CVD risk, with very high or extreme CVD risk seen in 20%, 48% and 61%, across the groups (p0.001 between CHB patients with and without hepatic steatosis and p0.05 between CHB patients with hepatic steatosis and NAFLD patients). In conclusion, there was a high proportion of CHB patients with hepatic steatosis, which should be diagnosed, as they may have more severe liver disease, so that this and their metabolic risk factors can be assessed and managed accordingly for a better long-term outcome.
تدمد: 1365-2893
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a7ebb50119ed8b4bb76a892bb2963f
https://pubmed.ncbi.nlm.nih.gov/36606597
Rights: CLOSED
رقم الانضمام: edsair.doi.dedup.....d8a7ebb50119ed8b4bb76a892bb2963f
قاعدة البيانات: OpenAIRE